Several methods have been developed to measure angiotensin-converting enzyme (also known as kininase II), but none is at once simple, rapid and specific. The enzyme acts as a dipeptidyl carboxypeptidase (Skeggs et al., 1956; Dorer et al., 1974a) of no specificity, but of great selectivity. Thus the enzyme hydrolyses bradykinin more rapidly than any of its higher homologues (e.g. lysyl-bradykinin; Dorer et al., 1974b) and has a greater affinity for des-Asp1-angiotensin I than for angiotensin I (Tsai et al., 1975; Chiu et al., 1976) .
The most commonly used assay method measures angiotensin-converting enzyme activity in terms of the rate of release of hippurate from hippurylhistidyl-leucine (Cushman & Cheung, 1971) . Reac- tions are terminated by acidification and then hippurate is separated from unhydrolysed substrate by extraction with ethyl acetate. Hippurate is quantified by measuring its A228. Ethyl acetate absorbs strongly at 228 nm and all traces must be removed by evaporation. The residue must be dissolved in water or in 0.9 % NaCl before quantification of hippurate (cf. Lieberman, 1975) . Thus the assay is tedious, time-consuming and subject to a number of artifacts. Lipaemic or haemolysed serum samples cannot be used. Similarly, detergents such as Triton X-100 interfere with absorbance readings.
Assays using hippurylglycylglycine have been developed, the best characterized of which measures the release of glycylglycine with a quantitative ninhydrin reaction (e.g. see Dorer et al., 1976 ). Hippurylglycylglycine appears to be somewhat superior to hippurylhistidyl-leucine in that it is less susceptible to hydrolysis by carboxypeptidase enzymes. However, the assay method of Dorer et al. (1976) dissolved in 0.5ml of 0.1 % (w/v) acetic acid, to which 5mg of 10% Pd/C catalyst was added. The mixture was treated with 5 Ci of 3H2 gas at 53 kPa (400 torr) for 3 h at room temperature. Solvent was removed by evaporation under vacuum, and the product was dissolved in methanol/water (1: 1, v/v) and separated from the catalyst by filtration. The solvent was removed under vacuum, and the product was dissolved in 3 ml of water and then freeze-dried. The product (128mCi, specific radioactivity 25 Ci/mmol) was dissolved in 7.11 ml of water. The product behaved as a single substance, not distinguishable from authentic hippurylglycylglycine, on paper electrophoresis at pH2.0 and 5.0 (Ryan et al., 1971 ) and on t.l.c.
[silica-gel plates (New England Nuclear); solvent systems: (a) butan-1-ol/acetic acid/water (4:1:5, by vol); (b) butan-1-ol/ethyl acetate/acetic acid/water (1:1:1:1, by vol.).
Results and Discussion
The [3H]hippurylglycylglycine can be used without carrier hippurylglycylglycine to yield a reaction with angiotensin-converting enzyme that obeys first-order ,nzyme kinetics. However, to facilitate comparison with the assay described by Dorer et al. (1976) , we used hippurylglycylglycine at a final concentration of 8 mm (apparent Km = 5mM) and [3H] hippurylglycylglycine at a final specific radioactivity of 0.125Ci/ mmol.
The conditions selected for assay of angiotensinconverting enzyme were those suggested by data of Dorer et al. (1976 We have used the assay to measure angiotensinconverting enzyme activity in sera of man, rat and guinea pig and in homogenates of rat kidney and guinea-pig lung (Table 1 ). The enzymic activity of the sera and tissue homogenates tested is indistinguishable from angiotensin-converting enzyme. The activity is inhibited (50%) by: 0.1 mM-EDTA; 2.8 nM-bradykinin-potentiating peptide 9a; 1/AMbradykinin-potentiating peptide 5ca; 12uM-angiotensin I; 6#uM-bradykinin. Bradykinin-potentiating peptides 9c and 5a [derived from the venom of Bothrops jararaca (South American pit viper)] are reported to be specific inhibitors of converting enzyme (for review see Bakhle, 1974) . The human serum enzyme as measured by our assay shared characteristics of pure pig lung angiotensin-converting enzyme . It required Cland was most active at pH 8.0. Further to test the specificity of the assay, serum samples (from healthy volunteers, patients with active Table 1 . Angiotensin-converting enzyme activity of sera and tissue homogenates Assays were performed as described in the text, taking care to limit substrate utilization to 10% or less. The results are means±s.D. for the numbers of determinations in parentheses. Specific activities for sera are expressed in munits/ml and specific activities for homogenates are expressed in munits/g wet wt.
of tissue. The mean value (±S.D.) for one human serum sample (from a patient with active sarcoidosis) assayed 28 times over 14 days was 179+7munits/ml. The coefficient of variation was 3.6°%. sarcoidosis and guinea pigs) were examined for their ability to form radioactive products other than hippurate. After incubation ofthe sera with substrate, the ethyl acetate extracts were evaporated (to approx. 0.1 ml) and were then applied to silica-gel thin-layer plates. The plates were developed in solvent system (b). In each experiment, all radioactivity was associated with hippurate (RF 0.71) and unhydrolysed substrate (RF 0.49) . None was associated with benzoic acid (RF 0.82) or hippurylglycine (RF 0.59). 'These results, together with those of the inhibition :studies, suggest that enzymes other than angiotensinconverting enzyme do not interfere. However, we cannot rule out the possibility that hitherto unrecognized enzymes (e.g. in abnormal sera not yet tested) may hydrolyse the substrate. Lieberman (1975) has shown that angiotensinconverting enzyme concentrations are increased in sera of some patients with active sarcoidosis, a finding confirmed by a number of independent investigators (e.g. Silverstein et al., 1976; Zorn et al., 1977) . Most of the clinical studies have used hippurylhistidyl-leucine as the assay substrate and have measured the rate of release of hippurate by the method of Cushman & Cheung (1971) or the rate of release of histidyl-leucine (e.g. . The latter product forms a strong fluorophor on reaction with o-phthaldialdehyde (Piquilloud et al., 1970) . To compare our assay method with that of Cushman & Cheung (as modified by Lieberman, 1975 , 1976 , we used both assays to measure angiotensin-converting enzyme activity of 94 human sera. A linear correlation was obtained (r = 0.891, P<0.001). One unit of enzyme activity as defined by Lieberman (1976) is equivalent to 3.6munits of enzyme activity as measured by our assay. Gavras et al. (1974) have shown that bradykininpotentiating peptide 9a (also known as SQ 20881) can be used to treat renin-related hypertensive cardiovascular disease. At present, it is not known what degree of inhibition of angiotensin-converting enzyme is required to obtain a therapeutic effect. To improve understanding of the clinical use of bradykinin-potentiating peptide 9o and other inhibitors ofangiotensin-converting enzyme, we measured arterial plasma enzyme activities of anaesthetized guinea pigs before and after a single intravenous injection of bradykinin-potentiating peptide. The results shown in Table 2 suggest that serial measurements of serum angiotensin-converting enzyme may be useful for monitoring treatment of patients with bradykinin-potentiating peptide 9a and other inhibitors ofangiotensin-converting enzyme (e.g. SQ 14225; Ondetti et al., 1977) .
The major advantages of our assay over those used previously are simplicity and the shorter time required to obtain assay results. Prior dialysis ofenzyme source is not required and there is no need to evaporate organic solvents before quantifying hippurate. Quenching problems have not been encountered except on assay of haemolysed serum samples. Triton X-100 in concentrations up to 0.05% (v/v) in the final reaction mixture does not disturb the apparent partition coefficients of either hippurate or hippurylglycylglycine. Lipaemic serum samples sometimes cause the formation of stable emulsions on extraction with ethyl acetate, but the emulsions can be broken by centrifugation, repeated if necessary. The major disadvantage of our assay is that it requires a liquid-scintillation counter.
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